164 related articles for article (PubMed ID: 27037894)
1. Tfh cell-mediated humoral immune response and HBsAg level can predict HBeAg seroconversion in chronic hepatitis B patients receiving peginterferon-α therapy.
Zhang L; Zhang M; Li H; Chen Z; Luo A; Liu B; Chen M; Peng M; Ren H; Hu P
Mol Immunol; 2016 May; 73():37-45. PubMed ID: 27037894
[TBL] [Abstract][Full Text] [Related]
2. Circulating PD-1
Zhang L; Li H; Ren H; Hu P
Mol Immunol; 2018 Nov; 103():270-278. PubMed ID: 30340072
[TBL] [Abstract][Full Text] [Related]
3. Immune correlates of hepatitis B surface antigen spontaneous seroconversion in hepatitis B e antigen negative chronic hepatitis B patients.
Vyas AK; Sharma BC; Sarin SK; Trehanpati N
Liver Int; 2018 Jan; 38(1):38-49. PubMed ID: 28500636
[TBL] [Abstract][Full Text] [Related]
4. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
Ning Q; Han M; Sun Y; Jiang J; Tan D; Hou J; Tang H; Sheng J; Zhao M
J Hepatol; 2014 Oct; 61(4):777-84. PubMed ID: 24915612
[TBL] [Abstract][Full Text] [Related]
5. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
Li GJ; Yu YQ; Chen SL; Fan P; Shao LY; Chen JZ; Li CS; Yi B; Chen WC; Xie SY; Mao XN; Zou HH; Zhang WH
Antimicrob Agents Chemother; 2015 Jul; 59(7):4121-8. PubMed ID: 25941216
[TBL] [Abstract][Full Text] [Related]
6. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
Cao ZH; Ma LN; Zhang HW; Liu YL; Chen XY
J Dig Dis; 2013 Aug; 14(8):446-50. PubMed ID: 23615131
[TBL] [Abstract][Full Text] [Related]
7. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.
Wong VW; Wong GL; Yan KK; Chim AM; Chan HY; Tse CH; Choi PC; Chan AW; Sung JJ; Chan HL
Hepatology; 2010 Jun; 51(6):1945-53. PubMed ID: 20209602
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients.
Idilman R; Cinar K; Seven G; Bozkus Y; Elhan A; Bozdayi M; Yurdaydin C; Bahar K
J Viral Hepat; 2012 Mar; 19(3):220-6. PubMed ID: 22329377
[TBL] [Abstract][Full Text] [Related]
9. Comparison of hepatitis B virus core-related antigen and hepatitis B surface antigen for predicting HBeAg seroconversion in chronic hepatitis B patients with pegylated interferon therapy.
Wang ML; Liao J; Wei B; Zhang DM; He M; Tao MC; Chen EQ; Tang H
Infect Dis (Lond); 2018 Jul; 50(7):522-530. PubMed ID: 29463147
[TBL] [Abstract][Full Text] [Related]
10. Experimental HBsAg/anti-HBs complex assay for prediction of HBeAg loss in chronic hepatitis B patients treated with pegylated interferon and adefovir.
de Niet A; Jansen L; Zaaijer HL; Klause U; Takkenberg B; Janssen HL; Chu T; Petric R; Reesink HW
Antivir Ther; 2014; 19(3):259-67. PubMed ID: 24256626
[TBL] [Abstract][Full Text] [Related]
11. Circulating chemokine (C-X-C Motif) receptor 5(+) CD4(+) T cells benefit hepatitis B e antigen seroconversion through IL-21 in patients with chronic hepatitis B virus infection.
Li Y; Ma S; Tang L; Li Y; Wang W; Huang X; Lai Q; Zhang M; Sun J; Li CK; Abbott WG; Naoumov NV; Zhang Y; Hou J
Hepatology; 2013 Oct; 58(4):1277-86. PubMed ID: 23703545
[TBL] [Abstract][Full Text] [Related]
12. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients.
Ma H; Yang RF; Wei L
J Gastroenterol Hepatol; 2010 Sep; 25(9):1498-506. PubMed ID: 20796146
[TBL] [Abstract][Full Text] [Related]
13. Quantitative hepatitis B surface antigen combined with hepatitis B e antigen as sustained virological response predictors during extended therapy with Peginterferon alfa-2a for hepatitis B e antigen-positive chronic hepatitis B.
Chen J; Zhang DH; Xu CR; Zhu MY; Yang ZT; Gong QM; Yu DM; Zhang XX
J Clin Virol; 2015 Nov; 72():88-94. PubMed ID: 26476325
[TBL] [Abstract][Full Text] [Related]
14. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
[TBL] [Abstract][Full Text] [Related]
15. Recovery of circulating CD56
Liu N; Liu B; Zhang L; Li H; Chen Z; Luo A; Chen M; Peng M; Yin W; Ren H; Hu P
Int Immunopharmacol; 2018 Sep; 62():59-66. PubMed ID: 29990695
[TBL] [Abstract][Full Text] [Related]
16. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
[TBL] [Abstract][Full Text] [Related]
17. Models for predicting hepatitis B e antigen seroconversion in response to interferon-α in chronic hepatitis B patients.
Wang CT; Zhang YF; Sun BH; Dai Y; Zhu HL; Xu YH; Lu MJ; Yang DL; Li X; Zhang ZH
World J Gastroenterol; 2015 May; 21(18):5668-76. PubMed ID: 25987794
[TBL] [Abstract][Full Text] [Related]
18. [Factors influencing the curative effect in patients with HBeAgpositive chronic hepatitis B treated with peg-interferon α-2a].
Chen J; Zheng Q; Jiang J; Zheng J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Jul; 37(7):714-9. PubMed ID: 22886227
[TBL] [Abstract][Full Text] [Related]
19. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
He LT; Ye XG; Zhou XY
World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
[TBL] [Abstract][Full Text] [Related]
20. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z
Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
